In AMD patient-derived cybrids, the combination (P+Q) treatment promotes cellular metabolism and reduces ROS production by promoting mitochondrial biogenesis and increasing the expression of the SOD2 enzyme gene. The gene discussed is SOD2; the disease is age-related macular degeneration.